Plasmid

seqWell Launches First Assay-ready, 384-well Library Preparation Kit to Enable Ultra-high Throughput Plasmid and Synthetic Construct Sequencing

Retrieved on: 
Monday, March 18, 2024
Science, Biotechnology, Research, Medical Supplies, General Health, Health, Health Technology, Genetics, Entrepreneurship, Synthetic biology, NGS, Workflow, Plastic, Multimedia, Plasmid, DBTL

ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.

Key Points: 
  • ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.
  • View the full release here: https://www.businesswire.com/news/home/20240318055628/en/
    seqWell's ExpressPlex HT 384-well library prep kit is the first commercially available next-generation sequencing library preparation kit enabling multiplexing up to 6,144 samples in a pre-plated 384-well format.
  • (Graphic: Business Wire)
    “ExpressPlex HT was a natural step in broadening our portfolio of scalable, multiplex library preparation solutions,” said Jack Leonard, Chief Technology Officer at seqWell.
  • Massive multiplexing using 6,144 indices and a fully automated, 90-minute library preparation workflow enable 24-hour sample-to-answer turnaround for greater than 6,000 samples.

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

Retrieved on: 
Wednesday, March 6, 2024
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Plasmid, ATCC, Multimedia, Sale, Transfection, Cell, Antibody, HEK293, Patent, Poster, Immortalised cell line, ATCC (company), AAV, Vaccine

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Key Points: 
  • Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.
  • View the full release here: https://www.businesswire.com/news/home/20240305885603/en/
    The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line (ATCC®, catalog number ATCC CCL-10™) with the adenoviral E1 gene.
  • “The launch of our custom rAAV service and the first sale of rAAV made using our AE1-BHK cell line is a significant milestone for the company,” said James Brown, CEO and co-founder of Agathos Biologics.
  • “To our knowledge, this is the first sale of rAAV produced using triple transfection in a cell line other than HEK293.

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

Retrieved on: 
Thursday, March 7, 2024
Plasmid, Investment, Growth, Transfection, Series, LVV, CGT, Patient, AAV, Vaccine

SHENZHEN, China, March 7, 2024 /PRNewswire/ -- Shenzhen Eureka Biotechnology Co., Limited (EurekaBio), a leading upstream supplier in the cell and gene therapy field, announced the completion of its Series B+ financing, exceeding $40 million. The financing was led by YUEXIU INDUSTRIAL FUND, with participation from numerous well-known Chinese funds, as well as follow-on investments from U.S. funds.

Key Points: 
  • EurekaBio's core innovation lies in the EuLV™ Lentiviral Vector Production System, a cutting-edge technology that transforms the large-scale production of lentiviral vectors using stable cell lines and a serum-free suspension system.
  • In contrast to traditional transient transfection production methods, the EuLV™ Lentiviral Vector Production System eliminates the necessity for plasmids, resulting in cost savings related to plasmid production and streamlining the overall production process.
  • Moreover, the EuLV™ system adopts a high-density suspension culture, which substantially increases unit titer levels, reduces production batches and associated costs and meets the requirements of large-scale lentiviral vector production.
  • The EuLV™ system presents a next-generation solution for lentiviral vector production to power cell and gene therapies, and is also well positioned for global adoption.

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, PFS, YOY, General Motors, EVP, TGA, Messenger, US FDA, Entrepreneurship, CDMO, History, Organization, Plasmid, CGMP, CBO, Travel

MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board.

Key Points: 
  • "We are thrilled to have Mark join the Board, as a Director of the Company," said Dr. Masood Tayebi, Co-Founder and Chief Executive Officer of Bridgewest Group.
  • Mark currently serves as CEO of BioCina, a Bridgewest Group funded CDMO providing end-to-end biologics solutions for microbial, pDNA and mRNA modalities globally.
  • As CEO and Managing Director of Stelis Biopharma, Mark ushered efforts to build and qualify a state-of-the-art vaccine facility in record time.
  • I'm inspired by the vision we share and excited about the journey we will travel to realize it," said Mark W. Womack.

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, PFS, YOY, General Motors, EVP, TGA, Messenger, US FDA, Entrepreneurship, CDMO, History, Organization, Plasmid, CGMP, CBO, Travel

MIAMI and PERTH, Australia, March 5, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board.

Key Points: 
  • "We are thrilled to have Mark join the Board, as a Director of the Company," said Dr. Masood Tayebi, Co-Founder and Chief Executive Officer of Bridgewest Group.
  • Mark currently serves as CEO of BioCina, a Bridgewest Group funded CDMO providing end-to-end biologics solutions for microbial, pDNA and mRNA modalities globally.
  • As CEO and Managing Director of Stelis Biopharma, Mark ushered efforts to build and qualify a state-of-the-art vaccine facility in record time.
  • I'm inspired by the vision we share and excited about the journey we will travel to realize it," said Mark W. Womack.

Entos Pharmaceuticals Launches GMP Clinical Manufacturing Facility in Carlsbad, California

Retrieved on: 
Thursday, January 25, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Eye, Facility, Plasmid, PLV, DNA, Multimedia, GMP, Good manufacturing practice, Infection, IND, Medication, COVID-19, Myenteric plexus, Messenger, Vaccine

Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced the launch of its new Good Manufacturing Practices (GMP) manufacturing facility in Carlsbad, California.

Key Points: 
  • Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced the launch of its new Good Manufacturing Practices (GMP) manufacturing facility in Carlsbad, California.
  • View the full release here: https://www.businesswire.com/news/home/20240125096146/en/
    Entos Pharmaceuticals GMP Manufacturing Facility; Photo credit: Sean Hawkins, Facility Manager
    The state-of-the-art facility features 20,000 square feet of dedicated manufacturing space, including a lipid formulation production suite with additional suites dedicated to mRNA and plasmid DNA manufacturing.
  • “The successful commissioning of the site, followed by GMP batch manufacturing, exemplifies the potential of our facility.
  • The launch of this new Entos facility is a key step in the company’s global manufacturing strategy as it looks to establish a future manufacturing site in Edmonton, Alberta, Canada, to enable the commercial manufacturing of emerging transformative medicines for Entos and its valued partners.

Asimov launches LV Edge Packaging System to optimize lentivirus production

Retrieved on: 
Monday, January 29, 2024
Kernel, Synthetic biology, DNA, GMP, Risk, Transgene, Therapy, Transfection, CAD, Plasmid, Vaccine

BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

Key Points: 
  • BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.
  • By removing the need to transiently transfect three out of the four GMP plasmids, the LV Edge Packaging System reduces manufacturing cost and supply chain risk without compromising speed to market.
  • The LV Edge Packaging System achieves high harvest titers of over 1E8 TU/mL across multiple chimeric antigen receptor (CAR) transgenes and enables tuneable transgene expression in the transduced cell.
  • For more information on the LV Edge Packaging System, please visit: www.asimov.com/ LV

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

Retrieved on: 
Tuesday, January 16, 2024
Health, Medical Devices, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, Miami Beach Convention Center, Senior, CRL, CMC, Regulation, Patient, CTA, LVV, DNA, AAV, Education minister, GMP, Gene, Tecmar, IND, COA, Doctor of Philosophy, Investigational New Drug, RC2, Cell, CDMO, Commercialization, Plasmid, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.
  • Charles River will officially launch the off-the-shelf Rep/Cap plasmid offering during Advanced Therapies Week , January 16-19, at the Miami Beach Convention Center.
  • Join Dr. Baghirzade in the Gene Therapy Manufacturing Track as part of the Regulatory Alignment for Gene Therapy Manufacturing session to learn how to:
    Ensure alignment with phase-appropriate plasmid DNA, AAV, and lentiviral vector (LVV) manufacturing best practices
    Matthew Hewitt, B.A.
  • Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and capacity expansions to simplify complex supply chains and meet the growing global demand for plasmid DNA, viral vector, and cell therapy services.

Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034 - Shaping the Future of Rare Disease Treatment with Viral Vector Solutions - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023
Biotechnology, Genetics, Health, Plasmid, Gene editing, Messenger, Research, CRISPR, Catalent, DNA, Molecular biology, Element, Vivisection, Cell, Vaccine

The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • Overall world revenue for the viral vectors and plasmid DNA manufacturing market is forecast to surpass US$1.35 billion in 2024, with strong revenue growth through to 2034.
  • Viral vectors and plasmids are instrumental in the field of biotechnology, especially in the context of advancements like CRISPR-Cas9 gene editing.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising viral vectors and plasmid DNA manufacturing prices and recent developments.

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Retrieved on: 
Wednesday, December 13, 2023
RNA, Protein, Partnership, GM, Messenger, Research, MBA, DNA, GMP, Plasmid, Patient, Therapy, Vaccine

REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase.

Key Points: 
  • REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase.
  • Under the terms of the deal, Aldevron will receive global manufacturing and commercialization rights to the Codex® HiCap RNA Polymerase and Codexis will receive payments for near-term technical milestones, along with commercial milestones and sales-based royalties.
  • Codexis and Aldevron will work together to ensure a smooth changeover for customers during a transitional period.
  • “We’re excited to partner with Aldevron, a market-leading mRNA manufacturer, to increase our commercial penetration with a path to a GMP-grade version of our Codex® HiCap RNA Polymerase.